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Despite improved rational drug design and a remarkable progress in genomic, proteomic and high-
throughput screening methods, the number of novel, single-target drugs fell much behind 
expectations during the past decade. Multi-target drugs multiply the number of pharmacologically 
relevant target molecules by introducing a set of indirect, network-dependent effects. Parallel with 
this the low-affinity binding of multi-target drugs eases the constraints of druggability, and 
significantly increases the size of the druggable proteome. These effects tremendously expand the 
number of potential drug targets, and will introduce novel classes of multi-target drugs with 
smaller side effects and toxicity. Here we review the recent progress in this field, compare 
possible network attack strategies, and propose several methods to find target-sets for multi-target 
drugs. 
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1. Introduction: emergence and rationale of the multi-drug concept 
Recent drug development strategies were based on the emergence of potential targets in genomic and proteomic 
studies. Therefore, the currently followed drug-development paradigm can be summarized as to: (a) find a target 
of clinical relevance; (b) identify the ‘best-binder druggable molecule’ by high-throughput screening of large 
combinatorial libraries and/or by rational drug design based on the three-dimensional structure of the target; (c) 
provide a set of proof-of-principle experiments; and (d) develop a technology platform leading to clinical 
applications. However, despite all the considerable drug-development efforts undertaken, the number of 
successful drugs and novel targets fell significantly behind the expectations during past decades [1-3]. 
 
A number of novel strategies have been developed to overcome the target-shortage, and to add novel classes of 
drugs to development pipelines. Many of these drug development directions aim to influence multiple targets in 
a parallel fashion. One of the most widespread multiple target approaches, combination therapy is increasingly 
used to treat many types of diseases, such as AIDS, atherosclerosis, cancer and depression. As one of newly 
developed combination therapies, ‘multi-target lead discovery’ is a promising tool for the identification of 
unexpectedly novel effects of drug combinations [4-8]. Recently, initial steps have been taken to develop 
aptamer combinations against complex sets of targets [9]. 
 
Multiple target strategies have only been re-discovered by drug-developers. Snake and spider venoms are both 
multi-component systems, and plants also developed a combinative-strategy to defend themselves against 
pathogens. Additionally, traditional medicaments and remedies often contain multi-component extracts of 
natural products [10,11]. All these examples show that multiple target strategies have benefits, which were 
utilized as medicaments by our ancestors several thousand years ago, and withstood million-year evolutionary 
selection. 
 
Agents aiming only a single target (‘single-hits’) might not always affect complex systems in the desired way 
even if they completely change the behaviour of their immediate target. Single targets might have ‘back-up’ 
systems that are sometimes different enough not to respond to the same drug. Moreover, many cellular networks 
are robust and prevent major changes in their outputs despite dramatic changes in their constituents [12-15]. 
These considerations are independent of whether or not the pharmacological agent inhibits or activates its target. 
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2. Examples for multi-target strategies 
Several efficient drugs, such as salicylate, non-steroidal anti-inflammatory drugs (NSAIDs), metformin, anti-
depressants, anti-neurodegenerative agents, multi-target kinase inhibitors (such as Gleevec™, or the inhibitors 
of the kinase-maturating molecular chaperone, Hsp90) affect many targets simultaneously [7,16-24]. Multi-
target antibodies (in forms of diabodies, triabodies, tetrabodies and recombinant polyclonal antibodies) are 
increasingly used in cancer therapy to delay the development of resistance [25,26].  
 
We may find a large number of currently used terms to describe ligands that have multiple activities: the words 
balanced, binary, bivalent, dimeric, dual, mixed or triple are all used in combination with various suffixes, such 
as agonist, antagonist, blocker, conjugate, inhibitor or ligand. Various pharmacophores may have an increasing 
overlap, which actually gives an almost continuous spectrum starting from conjugates (or cleavable conjugates, 
which are actually a novel chemical form of combinational therapies) through overlapping pharmacophores till 
the highly integrated multi-target drugs (Figure 1; [7,19]). 
 
Multi-target drugs offer a magnification of the ‘sweet spot’ of drug discovery [1], meaning the overlap between 
pathways, which are interesting from the pharmacological point of view, and the hits of chemical proteomics, 
which represent those proteins, which can interact with druggable molecules (meaning small, hydrophobic 
molecules with a good bioavailability). The ‘sweet spot’ represents those few hundred proteins, which are both 
parts of interesting pathways and are druggable [1]. The option to allow indirect effects via network-contacts of 
multi-target drugs expands the first circle, since the number of those proteins, which are indirectly related to 
existing targets of pharmacologically important pathways, is by magnitudes greater than the number of the 
targets themselves. On the other hand, the low-affinity binding of multi-target drugs enlarges the second circle, 
since it eases the constraints of druggability. (Small, hydrophobic molecules bind to only a small subset of 
proteins with high affinity. However, the very same molecules interact with ten or even hundred times more 
proteins with increasingly lower and lower affinity. Low affinity binding here describes interactions with 
dissociation constants in the higher micromolar or even close to the milimolar range. Low affinity binding also 
implies a more transient interaction, where the off-rate is comparable or higher than the on-rate.) As a result of 
these combined effects the ‘sweet spot’ of drug discovery may easily become a wide ‘candy-field’ (Figure 2). 
 
3. Cellular networks: drug target maps 
Cellular networks help us to understand the complexity of the cell. In the network concept the complex system is 
perceived as a set of interacting elements, which are bound together by links. Links usually have a weight, 
which characterizes their strength (affinity, or propensity). Links may also be directed links, when one of the 
elements has a larger influence to the other than vice versa. In cellular networks the interacting molecules are 
considered as the elements, and their interactions form the weighted, but not necessarily directed links of the 
respective structural network. Alternatively, we may also envision directed links as representations of signalling 
or metabolic processes of the functional networks in the cell (Table 1. [27-29]). Cellular networks often form 
small worlds, where two elements of the network are separated by only a few other elements. Networks of our 
cells contain hubs, i.e. elements, which have a large number of neighbours. These networks can be dissected to 
overlapping modules, which form hierarchical communities [30-32]. However, this summary of the major 
features of cellular networks is largely a generalization, and needs to be validated through critical scrutiny of the 
datasets, sampling procedures and methods of data analysis at each network examined [33,34]. 
 
Cellular networks offer a lot of possibilities to point out their key elements as potential drug targets. As an 
example of these possibilities, signalling networks have interdigitated pathways and multiple layers of cross-
talks [35]. Special signalling elements, such as the PI-3-kinase, the Akt-kinase, or the insulin-receptor substrate-
family have been called ‘critical nodes’. These ‘critical nodes’ have multiple isoforms, and are important 
junctions of signalling pathways [36]. Both the bridge-elements of signalling networks providing cross-talks and 
the ‘critical nodes’ can be important targets of network-based drug development. Domain-specific target-
analysis of protein-protein interaction networks extends the map of physical interactions towards functional 
understanding. Domain-specific targets offer a larger flexibility and may actually reflect a family of multiple 
targets due to frequent ‘re-use’ of domain-variants as a result of modular evolution [37,38]. Elements of 
metabolic and cytoskeletal networks have also been analyzed as drug targets [39,40]. 
 
However, current databases of most cellular networks suffer a lot of uncertainties. Protein-protein interaction 
networks have a large number of false-positive entries, which makes the inclusion and assessment of low-
affinity interactions especially difficult. Moreover, current databases mostly give an averaged probability of the 
particular interaction. This does not take into account, if the two proteins are expressed at the same time, or they 
are located in the same cellular compartment at the same time. Most databases do not contain the information of 
the ratio of two interacting proteins in the given status of the particular healthy or ‘sick’ cell. Literature-derived, 
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‘evidence-based’ databases suffer from nomenclature and interpretation problems of the original data. However, 
recent advances connect protein-protein interaction databases with protein structure data, which make both the 
validation and prediction of protein-protein interactions more robust [41-43]. 
 
We may overcome with the above problem by using curated databases, which contain only the most valid, most 
accurate information. However, these databases will miss most low-affinity interactions, and we loose around 
80% of the available information due to our increased scrutiny. As an alternative approach we keep all 
information taking into account that our database becomes ‘fuzzy’ due to the inclusion of potentially false data. 
In this approach to correct the errors, we need highly integrated methods for network analysis, which are able to 
build in all the above information and take into account those less, which are in contradiction with most of the 
others. Advantageously, these integrated analytical tools should be used in a ‘zoom-in’ fashion, where the user 
may define the ‘integration-level’ of her choice. Low resolution network maps can be calculated fast, and by 
directing the user’s mind, show the most important ‘take-home messages’ of the analysis. Zooming-in to a high-
resolution analysis with the same, flexible method, will show the refined details of all available information and 
gives the user a large number of correct (and false) ideas to think about and to test in experiments either in the 
primary ‘hit areas’ of the low-resolution analysis, or the spots of specific interests based on other assumptions. 
 
4. Multi-target drugs are often low-affinity binders 
Development of a multi-target drug is likely to produce a drug, which is interacting with its target having a 
lower affinity than a single-target drug because it is unlikely that a small, drug-like molecule can bind to a 
number of different targets with equally high affinity. However, low-affinity drug binding is apparently not a 
disadvantage. For example, memantine (a drug used to treat Alzheimer’s disease) and other multi-target non-
competitive NMDA receptor antagonists show that low-affinity, multi-target drugs might have a lower 
prevalence and a reduced range of side-effects than high-affinity, single-target drugs [20,44]. The recent 
suggestion to use unstructured proteins, as a novel and un-explored field of drug-targets uses the beneficial 
effects of low-affinity, but rather specific binding, which has been shown extremely useful in regulation and 
signalling [45]. (Here again, low affinity binding denotes interactions with dissociation constants in the higher 
micromolar or even close to the milimolar range. Low affinity binding also implies a rather transient interaction, 
where the off-rate is comparable or higher than the on-rate.) 
 
Does low-affinity binding predict a low-efficiency? Not necessarily. A vast majority (>80%) of the cellular 
protein, signalling and transcriptional networks are in a low-affinity, or transient ‘weak linkage’ with each other. 
In metabolic networks, weak links are those reactions, which have a low flux [29,46]. In this paper we use the 
term ‘weak linker’ to denote small molecules and drugs that interact with cellular proteins having a low-affinity. 
Thus, most multi-target drugs are weak linkers. Because most links in cellular networks are weak, a low-affinity 
multi-target drug might be sufficient to achieve a significant modification. The recent paper of Bruce N. Ames 
[47] on the potential impact of micro-nutrients on disease-development is a good example of the profound 
effects emerging from seemingly minor interactions. Low affinity, ‘imperfect’ binding allows the development 
of special, cooperative binding-behaviour, which may lead to a switch-type activation setting a threshold for 
various cellular events, such as DNA-replication [48,49]. 
 
5. Identification of drug targets using the network approach: attack strategies  
Drug design strategies are mostly based on target-driven approaches, where an efficient compound to influence 
disease-related molecular target is sought. The network approach examines the effects of drugs in the context of 
cellular networks. In this model a drug-induced inhibition of a single target means that the interactions around a 
given target are eliminated, whereas partial inhibition can be modelled as a partial knockout of the interactions 
of the target.  
 
Cellular networks are usually damaged by random failures, such as the oxidative damage of free radicals, the 
indirect effect of somatic mutations as well as the complex phenomenon of ageing [50]. Opposed to this, drug-
driven network attacks are targeted to find the most efficient way to influence network behaviour. Several 
classes of drugs such as antibiotics, fungicides, anti-cancer drugs as well as numerous chemical compounds such 
as pesticides are designed to destroy the normal function of cellular networks.  
 
Networks have a number of vulnerable points, and, therefore, can be attacked in many ways (Figure 3). The 
first major insight identifying a set of ‘weak points’ in may natural networks came from the work of Albert-
Laszlo Barabasi and co-workers [30,51], who uncovered that many real-world networks (including cellular 
networks) have a more-less scale-free degree distribution, which means (in simple terms) that these networks 
have hubs (e.g. nodes with a much greater number of neighbours than average). If hubs are selectively attacked, 
the information-transfer in most scale-free networks soon becomes significantly hindered. In other words: hubs 
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are central points of networks. On the contrary, scale-free networks are highly resistant against random damage. 
These two features can be summarized as a ‘robust-but-fragile’ nature of scale free networks. As an illustration 
for the robustness, we may delete 99% of the Internet in random-attack strategy and the continuity of the 
network still remains, i.e. we could still use the Internet after such an attack, albeit it would be much slower than 
usual [52]. On the contrary, malicious attacks on hubs may follow a ‘greedy’ strategy meaning that degrees are 
continuously re-calculated after each attack and network elements are re-ranked. This greedy strategy is often 
more powerful, than using the original degrees of network elements throughout the whole process [53]. 
 
Hubs are the centres of networks only from the point of local network topology. Another approach for 
pinpointing central elements of network communication is to find those elements (or links), which are in a 
centred position not in the local, but in the global topology. Betweenness centrality of a link refers to the number 
of shortest paths between any two elements of the network across the given link. Betweenness centrality was 
worked out first in social networks [54] but later it became a preferred centrality measure to assess the presumed 
effect of targeted attacks on network stability. Inverse geodesic length (also called network efficiency) meaning 
the sum of the inverse of the shortest paths between network elements is a widely used indicator of network 
damage after the removal of links or elements [53,55,56]. Alternative measures of damaging element or link 
removal have also been worked out by Latora and Marchiori [57], which are based on monitoring of the 
performance of the whole network. 
 
Recent studies take into account the weights and directedness of network links. This is much closer to the real, 
cellular scenario, where protein-protein interactions are characterized by their affinity and/or prevalence (link 
weight) as well as direction (e.g. in form of signalling). The removal of the links with the highest weighted 
centralities is often more devastating to network behaviour than the removal of the most central links based on 
the un-weighted version of the same network topology [58]. 
 
Another recent approach is to take into account ‘mesoscopic’ centrality network topology measures, which are 
neither based on local information (such as hubs) or global information (such as betweenness centrality) on 
network structure. Motter et al. [59] found that the removal of ‘long-range’ links connecting elements lying in a 
long distance from each other has a profound impact on small-world networks, however, it fails to affect many 
scale-free networks. Another complication is caused by multi-layered networks [60], where various 
communities, modules are organized in a hierarchical fashion. These studies reveal that the utilization of the 
complex structural information of real world networks needs more sophisticated methods, such as an integrated 
assessment of link-density and network topology (Kovacs et al., manuscript in preparation). 
 
The network approach gained an increasing ground in helping drug target analysis by now. Flux-balance 
analysis (or metabolic control analysis) uses a large database of experimental data, and calculates all metabolic 
rates of the metabolic network assuming that the rates of reactions producing a metabolite must be equal with 
the rates of reactions, which consume it.  Flux-balance analysis of metabolic networks uncovers vulnerable 
points of parasite or pathological metabolisms providing potential targets for efficient drug action [39,61-63]. 
Comparison of cellular (transcriptional, signalling, protein-protein interaction, etc.) networks from various 
genomes helps to identify the function of novel proteins and thus increases the number of potential drug targets 
[64,65]. Analysis of protein-protein interactions identifies protein contact surfaces as potential sites of drug 
action [66] and neural networks have long been applied in the methodological and computational help of drug 
design [67]. 
 
Most of the above network-related methods have been used so far to steer target-identification attempts to single 
targets and a systematic network-based analysis of multi-target drug action is still to come. In our earlier study 
[55,68] we modelled a multi-target ‘attack’ on the genetic regulatory networks of the bacterium Escherichia coli 
or the yeast Saccharomyces cerevisiae. A comparison of various strategies suggested that multiple but partial 
attacks on carefully selected targets were almost inevitably more efficient than the knockout of a single target. 
For example, the largest damage to the E. coli regulatory network was reached by removing an element with 72 
connections. However, the same damage could be achieved, if 3 to 5 nodes were partially inactivated. Multiple 
attacks proved to be more efficient than a single attack even if the number of affected interactions remained the 
same [55,68]. Thus, the reason underlying the efficiency of multi-target attacks was proved to be not trivial even 
from a theoretical point of view: multi-target attacks were not only better because they affected the network at 
more sites, they could, especially if distributed in the entire network, perturb complex systems more than 
concentrated attacks even if the number of targeted interactions remained the same.  
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5. ‘Network diseases’ 
Our initial network-based analysis of the potential efficiency of multi-target drugs [55,68] was based on the 
topology of bacterial and yeast gene regulatory networks, which may be regarded as an initial model of the 
multi-target action of antibiotics and fungicides, where network damage corresponds well to the desired drug 
action. For the analysis of multi-target drugs affecting specific disease models (e.g. anti-hypertensive, anti-
psychotic and anti-diabetic drugs), more specific signalling, metabolic and transcriptional network models are 
needed. As a prelude of this process several complex, multifactorial diseases have already been described as 
‘network diseases’. Cancer was assessed as a ‘systems biology disease’ by Hornberg et al. [69]. The complexity 
of intra- and extra-cellular cancer-specific changes in signalling, gene-regulatory (and, most probably, protein-
protein interaction) networks, the profound reorganization of cellular metabolism, the multiple types and 
interactions of cells involved, and the complexity of all these events at various types and subtypes of malignant 
transformation indeed, make the name, ‘systems biology disease’ well deserved for all stages of tumour 
development.  
 
Network-effects of continuously changing functional neuron-assemblies may provide an explanation of the daily 
fluctuations in the symptoms of neurodegenerative diseases. This approach may show novel pathways of drug 
development leading to shorter and cheaper clinical trials, which concentrate on the short-term attenuation of 
symptom-fluctuations instead of waiting for and monitoring the long-term, and rather elusive benefits of 
inhibited neurodegeneration [70]. Since increased fluctuations of the efficiency may reflect a general decline in 
the stability of the overall network – which is related to the reduction of weak links [29,46] – multi-target drugs, 
in fact, might be an ideal choice to prevent the further functional loss in this sense. The complexity of neuronal 
networks also led the concept of network-disease in case of depression aiding the design of novel, multi-target 
anti-depressants [7]. 
 
Last, but not least ageing has also been conceived as a ‘network disease’ [50,71]. The multiple reasons and 
stages of biological ageing, the increasing variability of symptoms and malfunctions both from one elderly 
person to the other and from one day to another all call for a network-based analysis of the increasing amount of 
data collected so far.   
 
6. Target-sets of multi-target drugs – the help of networks 
How should we find the relevant target-sets of multi-target drugs? In the last decade several experimental and 
modelling approaches have been developed to identify single targets in a network context [39,61,62,72-75]. 
Appropriate modifications of these approaches may constitute the first step for zooming-in to a smaller set of 
potential targets. A high-throughput combinative screen of all possible combinations may be a daunting task and 
prospect [5]. How could we pin-point those target-combinations, which might be relevant in the clinical setting? 
 
Surprisingly, ‘old fashioned’ drug development might come back here to help: in vivo pharmacology (i.e. whole-
animal studies) might become important again [76]. However, for more efficient in vivo testing, better animal 
models are needed. Better animal models can be achieved by ‘humanizing’ the metabolic and signalling network 
of test animals.  
 
Can the network approach help us to suggest potential target-sets? The answer is currently not known. However, 
we have many promising tools to assess the relevance of our present, network-based knowledge on the 
complexity of the cell in pathological states. We will list these in the “Expert opinion” section. 
 
7. Conclusions 
Combinatorial therapies recently become one of the most successful drug development strategies. Multi-target 
drugs can be perceived as siblings of combinatorial therapies, where the different agents (often as many as 5-6 
of them) are comprised to a single, integrated chemical entity. Multi-target drugs expand the number of 
pharmacologically relevant target molecules by introducing a set of indirect, network-dependent effects. Multi-
target drugs usually have a low affinity towards their targets. An increasing number of evidence shows that low 
affinity – especially, if multiplied – does not mean low efficiency. On the contrary, several signalling and 
regulatory events are actually based on low-affinity interactions. Moreover, low-affinity binding of multi-target 
drugs eases the constraints of druggability, and significantly increases the size of the druggable proteome. These 
effects tremendously expand the number of potential drug targets, and will introduce novel classes of multi-
target drugs with smaller side effects and toxicity. Cellular networks offer a large number of possibilities, such 
as hubs and bridges with high betweenness centrality to find target-sets of multi-target drugs. However, the 
‘fuzzyness’ (meaning uncertain and incomplete information) of cellular networks and the data-sets on ‘network 
diseases’ (such as cancer, diabetes and neurodegeneration) need a more sophisticated approach. 
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8. Expert opinion: Network-based, smart multi-target drugs of the future 
We predict that in 5-10 years multi-target drugs will be much more common than now. The emerging 
knowledge of recent years strongly suggests that these drugs have a better chance of affecting the complex 
equilibrium of whole cellular networks than drugs acting on a single target. Target-expansion to indirect targets 
will lead to the discovery of several novel classes of drugs. Moreover, it is sufficient that these multi-target 
drugs affect their targets only partially, which multiplies our target choices from the point of druggability. 
 
Low-affinity, multi-target drugs might have another advantage. Weak links have been shown to stabilize 
complex networks, including macromolecular networks, ecosystems and social networks, buffering the changes 
after system perturbations. If multi-target, low-affinity drugs inhibit their targets, they change a strong link into a 
weak link instead of eliminating the link completely. A weak activation also results in a weak link in most of the 
cases. Thus, multi-target drugs can increase the number of weak links in cellular networks and thus stabilize 
these networks in addition to having multiple effects. Stabilization of the cells becomes especially important, if 
we take into account that cells of stressed, sick and ageing organisms are at the ‘verge of chaos’, showing a 
much greater instability than their healthy counterparts [29,46,71,77,78]. Thus multi-target drugs may have 
multiple beneficial effects: 
• multi-target drugs can be designed to act on a carefully selected set of primary targets, which help to sum up 
the action of the drug on key, therapeutically relevant secondary targets; 
• via the above, ‘indirect’ approach, and their low affinity binding multi-target drugs may avoid the presently 
common dual-trap of drug-resistance and toxicity;  
• finally, the low affinity, ‘weak links’ of multi-target drugs have an important side-effect: they stabilize the 
sick cell, which may be sometimes at least as beneficial as their primary therapeutic effect. 
 
What are the 5-10 years perspectives to find the relevant target-sets of multi-target drugs? Here, our increasing 
knowledge of cellular networks will certainly play a key role in the future. The increasing complexity of the 
datasets requires more sophisticated tools to direct our attention to relevant areas of the information-universe. In 
the last part of our review we list a few ideas for future directions in the development of network analysis tool-
kits: 
• overlaps of network communities [31], which have a key role in the regulation of complex systems [29] 
may be efficient guides to restrict the initial target-pool in search of targets-sets for multi-target drugs; 
• differential analysis of relevant cellular networks (such as signalling networks, gene-regulatory networks, 
metabolic networks and protein-protein interaction networks) of healthy and ‘sick’ cells may provide an 
even more efficient screen; 
• finally, the current development of analytical tools to assess the ‘evolution’ and dynamism of whole cellular 
networks will reveal search methods to de-convolute the hidden masterminds of the primary target-sets from 
the currently known, pharmacologically relevant secondary-targets (Kovacs et al., patent application 
submitted). A variant of this approach has been called ‘reverse-engineering’, which deciphers potential 
targets by the analysis of the effect of a limited set of experimental perturbations [72,79-81]. These 
approaches open the way to find the multiple-targets, and to design ‘alternative target-sets’ to mimic the 
action of existing, successful drugs. 
In summary, 10 years from now we will have a multitude of expanded cellular datasets having detailed and 
differential information on variable pairs of ‘healthy’ and ‘sick’ cells. These datasets will have graded 
information, which enables to build weighted and directed networks. Analytical tools will be developed to assess 
the complexity of these networks keeping all data and giving a zoom-in picture of any resolution in a 
computationally accessible, short time. Multi-target drugs will magnify the currently available target field by 
introducing thousands of secondary targets as well as other thousands of druggable proteins. This will all lead to 
the discovery of several entirely novel drug classes. Finally we will enjoy the network option of ‘fine-tuning’ of 
drug action of multi-target drugs by targeted manipulation of certain elements of the already existing target-sets 
of multi-target drugs, which may lead to the development of ‘personalized medicines’ – at a low cost. 
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Table 1. Cellular networks as drug target maps. 
 
Name of cellular 
network 
Network elements Network links Potential drug 
targets 
Protein interaction 
network 
Cellular proteins Transient or 
permanent bonds 
hubs, bridges, 
proteins in 
modular centres 
and overlaps 
Cytoskeletal network Cytoskeletal filaments Transient or 
permanent bonds 
cross-linking 
proteins  
Organelle network Membrane segments 
(membrane vesicles, 
domains, rafts, of 
cellular membranes) 
and cellular organelles 
(mitochondria, 
lysosomes, segments of 
the endoplasmic 
reticulum, etc.) 
Proteins, protein 
complexes and/or 
membrane vesicles, 
channels 
proteins and lipid 
rafts regulating 
inter-organellar 
junctions 
Signalling network Proteins, protein 
complexes, RNA (such 
as micro-RNA) 
Highly specific 
interactions 
undergoing a profound 
change (either 
activation or 
inhibition), when a 
specific signal reaches 
the cell 
hubs, bridge 
proteins of cross-
talks, ‘critical 
nodes’ 
Metabolic network Metabolites, small 
molecules, such as 
glucose, or adenine, 
etc. 
Enzyme reactions 
transforming one 
metabolite to the other 
metabolic switch 
enzymes and 
their regulatory 
proteins, 
channelling 
Gene transcription 
network 
Transcriptional factors 
or their complexes and 
DNA gene sequences 
Functional (and 
physical) interactions 
between transcription 
factor proteins 
(sometimes RNA-s) 
and various parts of 
the gene sequences in 
the cellular DNA 
hubs, bridges, 
proteins in 
modular centres 
and overlaps 
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Figure 1. From combinational therapy to multi-target drugs. The increasing overlap of 
pharmacophores gives an almost continuous spectrum starting from conjugates (A) via 
slightly overlapping pharmacophores (B) till highly integrated multi-target drugs (C). 
 
 
 
 
 
Figure 2. From the ‘sweet spot’ of drug discovery to a potential candy-field. Multi-target 
drugs may magnify the ‘sweet spot’ of drug discovery [Brown and Superti-Furga, 2003] to a 
whole candy-field. (A) The overlap between pathways, which are interesting from the 
pharmacological point of view and the hits of chemical proteomics, which represent those 
proteins which can interact with druggable molecules constitutes the ‘sweet spot’ of drug 
discovery. (B) Indirect effects of multi-target drugs expands the number of pharmacologically 
relevant targets, while low-affinity binding enlarges the number of druggable molecules. 
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Figure 3. Attack scenarios on networks. In this figure we summarize a number of malicious 
attacks on vulnerable points of networks. (A) attacks on nodes with highest degree (hubs); (B) 
attacks on ‘hub-links’ with highest degree of their end-points; (C) attacks on bridging 
elements with links having a high betweenness centrality; (D) attacks on bridges having links 
with the highest weighted centrality. 
